Download PDF
Thromb Haemost 1987; 57(02): 171-175
DOI: 10.1055/s-0038-1651088
Original Article
Schattauer GmbH Stuttgart

Influence of Factor Xllla Activity on Human Whole Blood Clot Lysis In Vitro

J W C M Jansen
*   The Duphar B. V., Dept. Pharmacology, Weesp, The Netherlands
,
F Haverkate
**   The Gaubius Institute TNO, Leiden, The Netherlands
,
J Koopman
**   The Gaubius Institute TNO, Leiden, The Netherlands
,
H K Nieuwenhuis
***   The Dept. Haematology, University Hospital Utrecht, Utrecht, The Netherlands
,
C Kluft
**   The Gaubius Institute TNO, Leiden, The Netherlands
,
Th A C Boschman
*   The Duphar B. V., Dept. Pharmacology, Weesp, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 26 September 1986

Accepted after revision 18 December 1986

Publication Date:
28 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We studied the influence of Factor XIII a (F XIII a) activity on the lysis rate of fresh whole human blood clots, without using anticoagulants. Clotting was induced by exogenous thrombin, lysis by tissue-type Plasminogen Activator (t-PA) added before clotting. After various periods of time, lysis rates were determined by measuring the radioactivity in the supernatant of the clot originating from 125I-Fibrinogen added before clotting.

Lysis rates were determined in the presence of endogenous F XHIa and compared with those obtained after specific inhibition of F XIII a activity. We used an IgG fraction of an antiserum quenching the F XIII a activity. Addition of increasing amounts of the antibodies to normal blood resulted in a dramatic increase in clot lysis rate, concomitant with loss of F XIII activity. Lysis of blood clots from a patient with a congenital, homozygous, functional α2-Antiplasmin (α2-AP) deficiency (α2-AP-Enschede) was not or slightly increased by the anti F XIII antibodies indicating that fibrin-fibrin crosslinking per se does not contribute essentially to resistance of the blood clot against fibrinolysis. Both active α2-AP and F XIII a are required for the major part of the F XIII-dependent resistance of whole blood clots against lysis.

Keywords

α2-plasmin inhibitor - Blood clot lysis - Factor XIII
 

  • References

  • 1 Lorand L, Losowsky MS, Miloszewski K JM. Human factor XIII: fibrin stabilizing factor. In Progress in Hemostasis and thrombosis. Spaet Th H (Ed) Grune & Stratton; New York: 1980. 5 245-290
    Google Scholar
  • 2 Duckert F. Documentation of the plasma Factor XIII deficiency in man. Ann New York Acad Sci 1972; 202: 190-199
    CrossrefPubMedGoogle Scholar
  • 3 McDonagh RP, McDonagh J, Duckert F. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Brit J Haemat 1971; 21: 323-332
    CrossrefPubMedGoogle Scholar
  • 4 Kirkpatrick JP, Mclntire LV, Moake JL. Streptokinase induced degradation of crosslinked and uncrosslinked clots. Thromb Res 1978; 13: 569-575
    CrossrefPubMedGoogle Scholar
  • 5 Henderson KW, Nussbaum M. The mechanism of enhanced streptokinase induced clot lysis following in-vitro Factor XIII inactivations. Brit J Haemat 1969; 17: 445-453
    CrossrefPubMedGoogle Scholar
  • 6 Gormsen J, Fedderson C. Degradation of stabilized and non-stabilized fibrin clots by plasmin. Immunological study. Ann New York Acad Sci 1972; 202: 329-334
    CrossrefPubMedGoogle Scholar
  • 7 Folk JE, Finlayson JS. The Epsilon (y-Glutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 1977; 31: 1-133
    PubMedGoogle Scholar
  • 8 Haverkate F. Lysis of crosslinked and non-crosslinked purified fibrin. Thromb Diath Haemorrh 1975; 34: 584-585
    PubMedGoogle Scholar
  • 9 Sakata Y, Aoki N. Crosslinking of α2-plasmin inhibitor of fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-297
    CrossrefPubMedGoogle Scholar
  • 10 Sakata Y, Aoki N. Significance of crosslinking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and haemostasis. J Clin Invest 1982; 69: 536-542
    CrossrefPubMedGoogle Scholar
  • 11 Van Ruijven-Vermeer I AM, Nieuwenhuizen W. Purification of rat fibrinogen and its constituent chains. Biochem J 1978; 169: 653-658
    CrossrefPubMedGoogle Scholar
  • 12 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide 1, 3, 4, 6 tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 13 Nieuwenhuizen W, Emeis JJ, Vermond A, Kurver P, Van der Heide D. Studies on the catabolism and distribution of fibrinogen in rats. Application of the iodogen labelling technique. Biochem Biophys Res Commun 1980; 97: 49-55
    CrossrefPubMedGoogle Scholar
  • 14 Kluft C, Van Wezel AL, Van der Velden C AM, Emeis JJ, Verheijen JH, Wijngaards G. Large-scale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells. In Advances in Biotechnological processes. Mizrahi A, Van Wezel AL. (Eds) Alan R Liss; New York: 1983. 2 97-110
    Google Scholar
  • 15 Haverkate F, Brakman P. Fibrin plate assay. In Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1975. 1 151-159
    Google Scholar
  • 16 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 17 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res 1977; 10: 803-812
    CrossrefPubMedGoogle Scholar
  • 18 Koopman J, Haverkate F. Formation of fibrin degradation products from a non-anticoagulated whole blood clot. In Fibrinogen, Structure, Functional aspects, Metabolism. Haverkate F, Henschen A, Nieuwenhuizen W, Straub PW. (Eds) Walter de Gruyter; Berlin-New York: 1983: 255-260
    Google Scholar
  • 19 Inoshita K, Shanberge JN. A rapid quantitative assay method for fibrinstabilizing factor (Factor XIII). Am J Clin Pathol 1974; 61: 85-91
    CrossrefPubMedGoogle Scholar
  • 20 Kröninger A, Egbring R. Long-term treatment (12 years) with Factor-XIII concentrate in a patient with congenital Factor XIII deficiency. In Factor XIII and fibronectin. Egbring R, Klingemann HG. (Eds) Mediz Verlagsgesellschaft, Marburg/Lahn; W. Germany: 1983: 41-44
    Google Scholar
  • 21 Nieuwenhuis HK, Kluft C, Wijngaards G, Van Berkel W, Sixma JJ. α2-Antiplasmin Enschede: an autosomal recessive hemorrhagic disorder caused by a dysfunctional a2-antiplasmin molecule. Thromb Haemostas 1983; 50: 170
    PubMedGoogle Scholar
  • 22 Kluft C, Nieuwenhuis HK, Vellenga E. Congenital deficiencies in α2-antiplasmin. La Ricerca Clin Lab 1984; 14: 507-513
    PubMedGoogle Scholar
  • 23 Ferguson EW, Sander GE. Fibrin Epsilon (y-glutamyl) lysine crosslink acceleration by red blood cells. Nature 1979; 278: 183-185
    CrossrefPubMedGoogle Scholar
  • 24 Taylor FB, Carroll RC, Gerrard J, Esmon CT, Radcliffe RD. Lysis of clots prepared from whole blood and plasma. Fed Proc 1981; 40: 2092-2098
    PubMedGoogle Scholar
  • 25 Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14: 85-94
    CrossrefPubMedGoogle Scholar
  • 26 Rasche H. Influence of fibrin subunit structure on the resistance of clots to streptokinase-induced fibrinolytic activity. In Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (Eds) Raven Press; New York: 1985. 1 79-84
    Google Scholar
  • 27 Sakata Y, Mimuro J, Aoki N. Differential binding of plasminogen to crosslinked and non-crosslinked fibrin: its significance in hemostatic defect in Factor XIII deficiency. Blood 1984; 63: 1393-1401
    PubMedGoogle Scholar
  • 28 Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. J Biol Chem 1973; 248: 1395-1407
    PubMedGoogle Scholar
  • 29 Hartert H. Rheo-stimulation: a new method for the assay of clotting process and Factor XIII. A preliminary report. Biorheology 1974; 11: 355-360
    CrossrefPubMedGoogle Scholar
  • 30 Duckert F, Jung E, Schnerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-186
    PubMedGoogle Scholar
  • 31 Britton A FH. Congenital deficiency of factor XIII (fibrin-stabilizing factor). Am J Med 1967; 43: 751-761
    CrossrefPubMedGoogle Scholar